Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTUS
2024-514562-40-00Phase 2Completed
- Sponsor
- Avalo Therapeutics
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing AVTX-009 with Placebo to AVTX-009 (2 arms). Primary endpoint: HiSCR75 response at Week 16. Started Jan 2025; status: completed.
02
Drugs
abdakibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-514562-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514562-40-00.